Muna Therapeutics Overview

  • Year Founded
  • 2020

Year Founded

  • Status
  • Private

  • Employees
  • 19

Employees

  • Latest Deal Type
  • Series B
  • (Cancelled)

  • Investors
  • 12

Muna Therapeutics General Information

Description

Operator of a biopharmaceutical company intended to discover neurodegenerative therapies. The company's platform identifies new medicines to preserve cognition and other brain functions and operational resilience against neurodegenerative diseases, including Alzheimer's, frontotemporal dementia, and Parkinson's, enabling medical companies to help people suffering from neurodegenerative diseases access suitable therapeutics for rapid recovery.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Nordre Fasanvej 215
  • 2000 Frederiksberg
  • Denmark
Primary Industry
Drug Discovery
Vertical(s)
Corporate Office
  • Nordre Fasanvej 215
  • 2000 Frederiksberg
  • Denmark

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Muna Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Later Stage VC (Series B) 15-Oct-2025 Cancelled Generating Revenue
5. Grant 01-May-2026 Completed Generating Revenue
4. Grant 11-Oct-2022 Completed Generating Revenue
3. Early Stage VC (Series A) 09-Jul-2021 Completed Generating Revenue
2. Early Stage VC 31-Dec-2020 $6.05M $6.05M Completed Startup
1. University Spin-Out 22-Jan-2020 Completed Startup
To view Muna Therapeutics’s complete valuation and funding history, request access »

Muna Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Ordinary
Ordinary
Ordinary
Ordinary
Ordinary
Ordinary 14,652 $54.84 $54.84 1x $54.84 1.09%
Ordinary 121,904 $42.19 $42.19 1x $42.19 9.09%
To view Muna Therapeutics’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Muna Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a biopharmaceutical company intended to discover neurodegenerative therapies. The company's platform identif
Drug Discovery
Frederiksberg, Denmark
19 As of 2026

San Diego, CA
 

South San Francisco, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Muna Therapeutics Competitors (3)

One of Muna Therapeutics’s 3 competitors is Neuropore Therapies, a Corporation company based in San Diego, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Neuropore Therapies Corporation San Diego, CA
Denali Therapeutics Formerly VC-backed South San Francisco, CA
Inhibikase Therapeutics Corporation Wilmington, DE
You’re viewing 3 of 3 competitors. Get the full list »

Muna Therapeutics Patents

Muna Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026099455-A1 Dihydropyrrolopyrimidinone compounds as trem2 modulators Pending 08-Nov-2024
WO-2025191114-A1 Trem2 modulators Pending 14-Mar-2024
WO-2025191115-A1 Trem2 modulators Pending 14-Mar-2024
WO-2025157993-A1 Trem2 modulators Pending 24-Jan-2024
EP-4836962-A1 2-(tetrahydro-2h-pyran-4-yl)-7-methyl-8-oxo-6-(trifluoromethyl)-7,8-dihydropyrimido[5,4-d]pyrimidine derivatives as trem2 modulators for the treatment of neurodegenerative diseases Pending 04-Jan-2024 C07D487/04
To view Muna Therapeutics’s complete patent history, request access »

Muna Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Muna Therapeutics Investors (12)

Investor Name Investor Type Holding Investor Since Participating Rounds
Alzheimer's Association Corporation
VLAIO Limited Partner
Michael J. Fox Foundation Limited Partner
Droia Ventures Venture Capital Minority
EQT Life Sciences Venture Capital Minority
You’re viewing 5 of 12 investors. Get the full list »

Muna Therapeutics FAQs

  • When was Muna Therapeutics founded?

    Muna Therapeutics was founded in 2020.

  • Where is Muna Therapeutics headquartered?

    Muna Therapeutics is headquartered in Frederiksberg, Denmark.

  • What is the size of Muna Therapeutics?

    Muna Therapeutics has 19 total employees.

  • What industry is Muna Therapeutics in?

    Muna Therapeutics’s primary industry is Drug Discovery.

  • Is Muna Therapeutics a private or public company?

    Muna Therapeutics is a Private company.

  • What is Muna Therapeutics’s current revenue?

    The current revenue for Muna Therapeutics is .

  • How much funding has Muna Therapeutics raised over time?

    Muna Therapeutics has raised $85.1M.

  • Who are Muna Therapeutics’s investors?

    Alzheimer's Association, VLAIO, Michael J. Fox Foundation, Droia Ventures, and EQT Life Sciences are 5 of 12 investors who have invested in Muna Therapeutics.

  • Who are Muna Therapeutics’s competitors?

    Neuropore Therapies, Denali Therapeutics, and Inhibikase Therapeutics are competitors of Muna Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process